IBTA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IBTA is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is trading above the latest analyst target, fundamentals are weakening, and there is no strong proprietary buy signal. If you are impatient and want to act now, the better choice is to wait rather than buy at this level.
Current pre-market price is 35.2, sitting just below pivot 35.538 and between support at 34.837 and resistance at 36.239. The moving averages are bullish in the short-to-long sequence (SMA_5 > SMA_20 > SMA_200), which supports the trend, but MACD histogram is -0.264 and negatively expanding, showing weakening momentum. RSI_6 at 53.685 is neutral, so there is no strong overbought or oversold signal. Overall, the chart is mixed: trend structure is positive, but near-term momentum is soft and price is close to resistance.
["Short-term price structure remains constructive with SMA_5 > SMA_20 > SMA_200.", "Options positioning leans bullish based on a low 0.25 put-call open interest ratio.", "Pre-market price is still near the recent support/resistance zone, leaving room for a modest move if momentum improves.", "Earnings are scheduled for 2026-05-06 after hours, which could act as an event catalyst."]
["Evercore ISI lowered its price target to $29 from $32 and kept an In Line rating, which is below the current price of 35.2.", "Q4 2025 financials weakened: revenue fell 10.02% YoY, net income turned more negative, EPS declined sharply, and gross margin compressed.", "MACD is negative and worsening, indicating short-term momentum deterioration.", "News includes a disclosure-related legal issue tied to the IPO and Kroger contract, which adds headline risk.", "No strong insider or hedge fund accumulation trends were reported.", "No AI Stock Picker or SwingMax signal is present today."]
In 2025/Q4, Ibotta posted softer fundamentals. Revenue fell to 88.53 million, down 10.02% year over year. Net income dropped to -1.00 million, EPS declined to -0.04, and gross margin fell to 77.23 from the prior year, down 7.73%. The latest quarter shows contraction rather than growth, which is not ideal for a long-term buy case.
Recent analyst action is negative: Evercore ISI cut its price target to $29 from $32 and maintained an In Line rating. That implies the street sees limited upside. Wall Street pros appear cautious rather than bullish, with the current market price above the latest target and no evidence of a strong upgrade cycle. Recent trend: bearish-to-neutral.
